Cheap supplies of HIV-prevention jab for poorer countries hailed as ‘genuine chance to end’ global epidemic
The article reports that a new HIV-prevention injection called Lenacapavir will be made available at a low cost of $40 per patient per year in 120 low- and middle-income countries starting from 2027. This injection is hailed as the "next best thing" to an HIV vaccine and offers a "genuine chance to end" the global HIV epidemic. The affordable pricing of Lenacapavir has been made possible through agreements between the drug's manufacturer and generic drug producers. This development is seen as a significant step towards improving access to HIV-prevention tools in resource-limited settings, where the burden of the epidemic remains high. The article emphasizes the potential impact of this affordable injection in driving progress towards the goal of ending the global HIV epidemic, providing a new and effective prevention option for populations most affected by the virus.
Source: For the complete article, please visit the original source link below.
